Helen Do
Family · Garden Grove, CANPI 1386034296
Payments from drug & device makers
Across 212 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Boehringer Ingelheim$440
- Novo Nordisk$408
- Xeris Pharmaceuticals, Inc.$328
- Bayer$201
- Lilly USA, LLC$190
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,035100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 67 | $1,453 |
| Boehringer Ingelheim | 18 | $440 |
| Novo Nordisk | 16 | $408 |
| Xeris Pharmaceuticals, Inc. | 5 | $328 |
| Bayer | 10 | $201 |
| Lilly USA, LLC | 7 | $190 |
| Dexcom, Inc. | 5 | $181 |
| GSK | 7 | $164 |
| Almatica Pharma LLC | 5 | $141 |
| Johnson & Johnson(3 entities) | 6 | $139 |
| Gilead | 5 | $138 |
| AstraZeneca | 8 | $136 |
| AbbVie | 6 | $129 |
| Evofem Biosciences, Inc. | 6 | $115 |
| Redhill Biopharma Inc. | 6 | $109 |
| Dynavax Technologies Corporation | 5 | $93 |
| Hologic Sales And Service, LLC | 3 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $67 |
| Radius Health, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $46 |
| Biogen | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| UCB, Inc. | 1 | $34 |
| Insulet Corporation | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Intra-sana Laboratories | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Vivus LLC | 1 | $22 |
| Zimmer Biomet | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Cequr Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$268
- EVENITY$122
- Otezla$122
- Repatha$120
- Ozempic$120
How this compares
$5,049 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 122 | $201,195 |
| FarxigaDapagliflozin Propanediol | 258 | $199,650 |
| VascepaIcosapent Ethyl | 518 | $190,161 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 67 | $162,412 |
| JardianceEmpagliflozin | 159 | $103,882 |
| VemlidyTenofovir Alafenamide | 58 | $94,626 |
| TrulicityDulaglutide | 67 | $86,777 |
| TradjentaLinagliptin | 100 | $81,747 |
| Repatha SureclickEvolocumab | 127 | $80,385 |
| KerendiaFinerenone | 55 | $59,915 |
| LinzessLinaclotide | 65 | $49,895 |
| DapagliflozinDapagliflozin Propanediol | 69 | $47,121 |
| Praluent PenAlirocumab | 72 | $43,001 |
| JanuviaSitagliptin Phosphate | 46 | $41,294 |
| ZenpepLipase/Protease/Amylase | 30 | $39,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $1,453 | $363,607189 claims |
| AstraZenecaFarxiga | $136 | $199,650258 claims |
| Boehringer IngelheimJardiance, Tradjenta | $440 | $185,628259 claims |
| AbbVieLinzess, Restasis, Creon | $129 | $117,059144 claims |
| GileadVemlidy | $138 | $94,62658 claims |
| Lilly USA, LLCTrulicity | $190 | $86,77767 claims |
| BayerKerendia | $201 | $59,91555 claims |
| Aimmune Therapeutics, Inc.Zenpep | $67 | $39,64830 claims |
| Novo NordiskOzempic | $408 | $21,55714 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $12,65922 claims |
| GSKArexvy | $164 | $8,60831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Garden Grove
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.